Our Precision Antibody Discovery service rapidly identifies and expresses antibody sequences with a broad affinity range for your target and the most promising biophysical profiles for commercialization. Utilizing next generation sequencing (NGS) of your in vivo samples (i.e., B cells, PBMCs) or in vitro libraries (i.e., phage display) and the power of machine learning with our novel bioinformatic platform, AbXtract™, powered by OpenEye and developed by Specifica, this end-to-end workflow enables high-throughput screening of your library to generate 5 – 50x more antibody leads than traditional low-throughput approaches. This results in more functionally diverse leads, even including clonotypes and rare clones, improving antibody program success.
• NGS FASTQ files
• AbXtract report
• Expressed antibodies (mL to L expression scales available)
• Antibody QC report including SDS-PAGE analysis
Azenta Life Sciences is a service provider of cutting-edge NGS platforms. For information on our NGS platforms, as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing-only projects.